Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen Acquires Functional Proteomics Company Arcaris

NEW YORK, July 26 – Deltagen has signed an agreement to acquire functional proteomics company Arcaris in a cash and stock deal, the companies said Thursday.

To acquire Arcaris, Deltagen will issue 765,000 new shares of Deltagen common stock, pay $450,000 in cash, and reserve 50,000 shares of Deltagen common stock for Arcaris employee options. Based on Deltagen’s closing price Wednesday of $8.84, the combined cash and stock has a value of about $7.7 million. In addition, if Arcaris achieves certain milestones, Deltagen will pay Arcaris shareholders an additional 550,000 shares, valued at about $4.8 million based on Wednesday's closing price.

Deltagen, based in Menlo Park, Calif., has developed a database of functionally annotated mammalian genes based on data from mouse gene knockout models. Arcaris, to be renamed Deltagen Proteomics, will add its technology for generating peptide probes, studying their effects in cell-based assays, and detecting the probes to find the proteins bound to them. In addition, Arcaris will help Deltagen develop screens for small molecules against the protein drug targets the companies identify. 

"The acquisition of Arcaris is an important strategic extension to our current and future target validation and drug discovery platform,” William Matthews, CEO of Deltagen, said in a statement. “Having the ability to identify potential cellular targets that can be modulated with small molecules will clearly expand our own research efforts into new therapeutic classes as well as generating novel drug targets," he added.

Arcaris’ current president and CEO, Alexander Kamb, will join Deltagen's management team as vice president of research and development at Deltagen Proteomics. Arcaris currently has 28 employees, with 22 dedicated to research.

Deltagen’s subscribers to DeltaBase, its database of mammalian gene function information, are GlaxoSmithKline, Pfizer, and Vertex Pharmaceuticals. The company also provides drug target discovery services for GlaxoSmithKline, Merck, Pfizer, and Schering-Plough Research Institute.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.